[go: up one dir, main page]

RU2003114752A - TREATMENT OF GASTROINTESTINAL STOMAL TUMORS - Google Patents

TREATMENT OF GASTROINTESTINAL STOMAL TUMORS

Info

Publication number
RU2003114752A
RU2003114752A RU2003114752/15A RU2003114752A RU2003114752A RU 2003114752 A RU2003114752 A RU 2003114752A RU 2003114752/15 A RU2003114752/15 A RU 2003114752/15A RU 2003114752 A RU2003114752 A RU 2003114752A RU 2003114752 A RU2003114752 A RU 2003114752A
Authority
RU
Russia
Prior art keywords
methylpiperazin
ylamino
benzamide
ylmethyl
pyridin
Prior art date
Application number
RU2003114752/15A
Other languages
Russian (ru)
Other versions
RU2301066C2 (en
Inventor
Элизабет БУХДУНГЕР
Рено КАПДЕВИЛЛЬ
Джордж Даниел ДЕМЕТРИ
Саса ДИМИТРЬЕВИС
Брайан Дж ДРУКЕР
Джонатан А. ФЛЕТЧЕР
Хейкки ЙОЕНСУУ
Сандра Лита СИЛБЕРМАН
Дейвид ТУВЕСОН
Майкл С. ХЕЙНРИЧ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2003114752A publication Critical patent/RU2003114752A/en
Application granted granted Critical
Publication of RU2301066C2 publication Critical patent/RU2301066C2/en

Links

Claims (8)

1. Применение 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I1. The use of 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl] benzamide of the formula I
Figure 00000001
Figure 00000001
 или его фармацевтически приемлемой соли для приготовления фармацевтических композиций, предназначенных для лечения желудочно-кишечных стромальных опухолей.or a pharmaceutically acceptable salt thereof for the preparation of pharmaceutical compositions for the treatment of gastrointestinal stromal tumors. 2. Применение 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I2. Use of 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl] benzamide of the formula I
Figure 00000002
Figure 00000002
 или его фармацевтически приемлемой соли для лечения желудочно-кишечных стромальных опухолей.or a pharmaceutically acceptable salt thereof for the treatment of gastrointestinal stromal tumors. 3. Способ лечения человека, страдающего желудочно-кишечными стромальными опухолями, отличающийся тем, что человеку, нуждающемуся в таком лечении, вводят эффективную в отношении желудочно-кишечных стромальных опухолей дозу 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I3. A method of treating a person suffering from gastrointestinal stromal tumors, characterized in that a person in need of such treatment is administered an effective dose of 4- (4-methylpiperazin-1-ylmethyl) -N- against gastrointestinal stromal tumors [4 -methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl] benzamide of the formula I
Figure 00000003
Figure 00000003
 или его фармацевтически приемлемой соли.or a pharmaceutically acceptable salt thereof. 4. Применение или способ по п.3, согласно которому вводят фармацевтически приемлемую кислотно-аддитивную соль 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I.4. The use or method according to claim 3, wherein the pharmaceutically acceptable acid addition salt of 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidine is administered -2-ylamino) phenyl] benzamide of the formula I. 5. Применение или способ по п.3, согласно которому вводят метансульфонат 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I.5. The use or method according to claim 3, wherein 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino methanesulfonate is administered phenyl] benzamide of the formula I. 6. Применение или способ по п.3, согласно которому взрослому человеку вводят суточную дозу от 200 до 600 мг монометилсульфоната 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I.6. The use or method according to claim 3, according to which an adult is administered a daily dose of 200 to 600 mg of 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3) monomethyl sulfonate -yl) pyrimidin-2-ylamino) phenyl] benzamide of the formula I. 7. Способ введения больному человеку, имеющему желудочно-кишечные стромальные опухоли 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I7. Method of administration to a sick person having gastrointestinal stromal tumors 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl ] benzamide of the formula I
Figure 00000004
Figure 00000004
 или его фармацевтически приемлемой соли, отличающийся тем, что больному человеку вводят ежедневно в течение периода времени, превышающего 3 месяца, фармацевтически эффективное количество 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I или его фармацевтически приемлемой соли.or its pharmaceutically acceptable salt, characterized in that the sick person is administered daily for a period of time exceeding 3 months, a pharmaceutically effective amount of 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4- pyridin-3-yl) pyrimidin-2-ylamino) phenyl] benzamide of the formula I or a pharmaceutically acceptable salt thereof. 8. Способ по п.7, согласно которому вводят суточную дозу от 200 до 600 мг монометансульфоната 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I.8. The method according to claim 7, according to which a daily dose of 200 to 600 mg of 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidine monomethanesulfonate is administered -2-ylamino) phenyl] benzamide of the formula I.
RU2003114752/15A 2000-10-27 2001-10-26 Method for treating gastrointestinal stromal tumor cases RU2301066C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27
US60/243,810 2000-10-27

Publications (2)

Publication Number Publication Date
RU2003114752A true RU2003114752A (en) 2004-09-10
RU2301066C2 RU2301066C2 (en) 2007-06-20

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003114752/15A RU2301066C2 (en) 2000-10-27 2001-10-26 Method for treating gastrointestinal stromal tumor cases

Country Status (25)

Country Link
US (1) US6958335B2 (en)
EP (1) EP1332137B1 (en)
JP (1) JP4386635B2 (en)
KR (1) KR100885129B1 (en)
CN (1) CN1276754C (en)
AT (1) ATE321556T1 (en)
AU (2) AU2002218262B2 (en)
BR (1) BRPI0114870B8 (en)
CA (1) CA2424470C (en)
CY (1) CY1105055T1 (en)
CZ (1) CZ303944B6 (en)
DE (1) DE60118430T2 (en)
DK (1) DK1332137T3 (en)
ES (1) ES2260317T3 (en)
HU (1) HU229106B1 (en)
IL (2) IL155029A0 (en)
MX (1) MXPA03003703A (en)
NO (1) NO324948B1 (en)
NZ (1) NZ525254A (en)
PL (1) PL209733B1 (en)
PT (1) PT1332137E (en)
RU (1) RU2301066C2 (en)
SK (1) SK287335B6 (en)
WO (1) WO2002034727A2 (en)
ZA (1) ZA200302155B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
AU2002342335B2 (en) * 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
PT1401415E (en) * 2001-06-29 2006-09-29 Ab Science USING N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2003004006A2 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
WO2003002106A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitions for treating allergic diseases
WO2003003006A2 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
ATE343415T1 (en) * 2001-06-29 2006-11-15 Ab Science THE USE OF C-KIT INHIBITORS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
CA2460845A1 (en) * 2001-09-20 2003-03-27 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
EP1461032B1 (en) * 2001-09-20 2008-07-16 AB Science Use of c-kit inhibitors for promoting hair growth
CA2477111A1 (en) * 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating cns disorders
FR2844452A1 (en) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Modulating dendritic cell activity, e.g. for treatment of viral infections, NK-sensitive tumors or autoimmune diseases, using inhibitors or specific tyrosine kinases, e.g. c-abl, bcr/abl and c-kit
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
BRPI0414527A (en) * 2003-09-19 2006-11-07 Novartis Ag treatment of gastrointestinal stromal tumors with imatinib and midostaurin
US20100210596A1 (en) * 2006-02-01 2010-08-19 Bluestone Jeffrey A Use of aminopyrimidine compounds in the treatment of immune disorders
KR101433629B1 (en) * 2006-09-11 2014-08-27 쿠리스 인코퍼레이션 Tyrosine kinase inhibitor containing a zinc binding moiety
KR20090077914A (en) * 2006-09-11 2009-07-16 쿠리스 인코퍼레이션 Multifunctional Small Molecules as Antiproliferative Agents
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (en) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 Composition containing quinazoline derivatives, preparation method and use
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
BR112013022552B1 (en) 2011-03-04 2021-11-23 Newgen Therapeutics, Inc QUINAZOLINE COMPOUNDS REPLACED WITH ALCINE, THEIR USE, PHARMACEUTICAL COMPOSITION, AND KIT
WO2012155339A1 (en) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof
SG11201405099UA (en) 2012-02-21 2014-10-30 Ranbaxy Lab Ltd Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CA2880236C (en) 2012-07-27 2022-09-13 Antonius Martinus Gustave Bunt Efflux inhibitor compositions and methods of treatment using the same
EP3027026B1 (en) 2013-07-31 2024-11-13 Avalyn Pharma Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2019016673A2 (en) 2017-07-20 2019-01-24 Kashiv Pharma Llc A stable oral pharmaceutical composition of imatinib
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
JP7523351B2 (en) 2018-01-31 2024-07-26 デシフェラ・ファーマシューティカルズ，エルエルシー Combination Therapy for the Treatment of Mastocytosis - Patent application
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers
TWI878335B (en) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 Methods of treating gastrointestinal stromal tumors
EP4013412A1 (en) 2019-08-12 2022-06-22 Deciphera Pharmaceuticals, LLC Ripretinib for treating gastrointestinal stromal tumors
IL293866A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Amorphous kinase inhibitor formulations and methods of use thereof
LT4084779T (en) 2019-12-30 2024-11-11 Deciphera Pharmaceuticals, Llc COMPOSITIONS
KR102535840B1 (en) 2020-07-31 2023-05-23 (주)파로스아이바이오 Use of 2,3,5-Substituted Thiophene Compound for Prevention, Improvement or Treatment of Gastrointestinal Stromal Tumor
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1528449A1 (en) * 1985-06-05 1989-12-15 Центральный институт усовершенствования врачей Method of relaxation of ileocecal section of intestine
TW225528B (en) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (en) * 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
WO2000012084A1 (en) * 1998-08-31 2000-03-09 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity

Similar Documents

Publication Publication Date Title
RU2003114752A (en) TREATMENT OF GASTROINTESTINAL STOMAL TUMORS
JP2004512328A5 (en)
BRPI0114870B8 (en) use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-amino)phenyl]-benzamide for the manufacture of pharmaceutical compositions for treatment of gastrointestinal stromal tumors
KR102293847B1 (en) Use of masitinib for the treatment of a subpopulation of patients with amyotrophic lateral sclerosis
JP2008509187A5 (en)
PT1227806E (en) PHARMACEUTICAL FORMULA CONTAINING TOLTERODINE AND ITS UTILIZATION
RU2002123350A (en) Dipeptidnitrile Cathepsin K Inhibitors
RU2007108861A (en) TRIFTOMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS
JP2005502643A5 (en)
JO2371B1 (en) 4-phenyl -pyridine derivatives
JP2009532438A5 (en)
CN102647986A (en) Methods of treating proliferative disorders and other pathological conditions mediated by BCR-ABL, C-KIT, DDR1, DDR2 or PDGF-R kinase activity
RU2008143703A (en) The use of c-Src inhibitors in combination with pyrimidylamine benzamide for the treatment of leukemia
MD523G2 (en) New triazol pyrimidine derivatives, angiotension II antagonist, processes for preparation thereof, pharmaceutical compositions containg thereof
RU2005138124A (en) DERIVATIVES OF TETRAHYDROCARBASOL AND THEIR PHARMACEUTICAL USE
ATE366107T1 (en) USE OF SULFODEHYDROABIETIC ACID TO TREAT INFLAMMATORY BOWEL DISEASE
JP2006505582A5 (en)
RU2004126447A (en) TREATMENT OF RHEUMATOID ARTHRITIS
AU2003232805A8 (en) Pharmaceutical active substance combination and the use thereof
CA2504665A1 (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
DE60019968D1 (en) USE OF GEPIRONE METABOLITE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF NEUROLOGICAL DISEASES
RU98106104A (en) Pyrimidine derivatives
RU2004112422A (en) ROUVASTATIN IN PREDEDENTIONAL CONDITIONS
HRP20100265T1 (en) Mixture of Pyrimidylaminobenzamide Compounds and Imatinib for the Treatment or Prevention of Proliferative Diseases
KR20060130619A (en) Combination of organic compounds